386 related articles for article (PubMed ID: 25145835)
21. A small cell variant of ALK-positive, CD8-positive anaplastic large cell lymphoma with primary subcutaneous presentation mimicking subcutaneous panniculitis-like T-cell lymphoma.
Wang E; Papalas J; Siddiqi I; Stoecker M; Rehder C; Sebastain S; Burchette J; Huang Q
Pathol Res Pract; 2011 Aug; 207(8):522-6. PubMed ID: 21763080
[TBL] [Abstract][Full Text] [Related]
22. EMMPRIN (CD147) is induced by C/EBPβ and is differentially expressed in ALK+ and ALK- anaplastic large-cell lymphoma.
Schmidt J; Bonzheim I; Steinhilber J; Montes-Mojarro IA; Ortiz-Hidalgo C; Klapper W; Fend F; Quintanilla-Martínez L
Lab Invest; 2017 Sep; 97(9):1095-1102. PubMed ID: 28581487
[TBL] [Abstract][Full Text] [Related]
23. NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma.
Leventaki V; Drakos E; Medeiros LJ; Lim MS; Elenitoba-Johnson KS; Claret FX; Rassidakis GZ
Blood; 2007 Sep; 110(5):1621-30. PubMed ID: 17416736
[TBL] [Abstract][Full Text] [Related]
24. Involvement of oncogenic tyrosine kinase NPM-ALK in trifluoperazine-induced cell cycle arrest and apoptosis in ALK
Hu L; Zhang X; Wang J; Wang S; Amin HM; Shi P
Hematology; 2018 Jun; 23(5):284-290. PubMed ID: 29086626
[TBL] [Abstract][Full Text] [Related]
25. Consequences of heat shock protein 72 (Hsp72) expression and activity on stress-induced apoptosis in CD30+ NPM-ALK+ anaplastic large-cell lymphomas.
Bonvini P; Zorzi E; Mussolin L; Pillon M; Romualdi C; Peron M; d'Amore ES; Lamant L; Rosolen A
Leukemia; 2012 Jun; 26(6):1375-82. PubMed ID: 22289917
[TBL] [Abstract][Full Text] [Related]
26. STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma.
Wu C; Molavi O; Zhang H; Gupta N; Alshareef A; Bone KM; Gopal K; Wu F; Lewis JT; Douglas DN; Kneteman NM; Lai R
Blood; 2015 Jul; 126(3):336-45. PubMed ID: 25921060
[TBL] [Abstract][Full Text] [Related]
27. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Younes A
Exp Hematol; 2006 Dec; 34(12):1670-9. PubMed ID: 17157164
[TBL] [Abstract][Full Text] [Related]
28. Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.
Bohling SD; Jenson SD; Crockett DK; Schumacher JA; Elenitoba-Johnson KS; Lim MS
Leuk Res; 2008 Mar; 32(3):383-93. PubMed ID: 17720243
[TBL] [Abstract][Full Text] [Related]
29. Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options.
Querfeld C; Khan I; Mahon B; Nelson BP; Rosen ST; Evens AM
Oncology (Williston Park); 2010 Jun; 24(7):574-87. PubMed ID: 20669794
[TBL] [Abstract][Full Text] [Related]
30. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
Bonvini P; Gastaldi T; Falini B; Rosolen A
Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
[TBL] [Abstract][Full Text] [Related]
31. Detection of a subset of CD30+ anaplastic large cell lymphoma by interphase fluorescence in situ hybridization.
Shin HJ; Thorson P; Gu J; Katz RL
Diagn Cytopathol; 2003 Aug; 29(2):61-6. PubMed ID: 12889041
[TBL] [Abstract][Full Text] [Related]
32. Use of an anti-ALK antibody in the characterization of anaplastic large-cell lymphoma of childhood.
Hutchison RE; Banki K; Shuster JJ; Barrett D; Dieck C; Berard CW; Murphy SB; Link MP; Pick TE; Laver J; Schwenn M; Mathew P; Morris SW
Ann Oncol; 1997; 8 Suppl 1():37-42. PubMed ID: 9187427
[TBL] [Abstract][Full Text] [Related]
33. Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas.
Boi M; Zucca E; Inghirami G; Bertoni F
Br J Haematol; 2015 Mar; 168(6):771-83. PubMed ID: 25559471
[TBL] [Abstract][Full Text] [Related]
34. Flow cytometric detection of circulating tumour cells in nucleophosmin/anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: comparison with quantitative polymerase chain reaction.
Damm-Welk C; Schieferstein J; Schwalm S; Reiter A; Woessmann W
Br J Haematol; 2007 Aug; 138(4):459-66. PubMed ID: 17608768
[TBL] [Abstract][Full Text] [Related]
35. The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation.
Hübinger G; Scheffrahn I; Müller E; Bai R; Duyster J; Morris SW; Schrezenmeier H; Bergmann L
Exp Hematol; 1999 Dec; 27(12):1796-805. PubMed ID: 10641597
[TBL] [Abstract][Full Text] [Related]
36. HuR-mediated control of C/EBPbeta mRNA stability and translation in ALK-positive anaplastic large cell lymphomas.
Bergalet J; Fawal M; Lopez C; Desjobert C; Lamant L; Delsol G; Morello D; Espinos E
Mol Cancer Res; 2011 Apr; 9(4):485-96. PubMed ID: 21343335
[TBL] [Abstract][Full Text] [Related]
37. Immunohistopathological features of anaplastic large-cell lymphoma according to anaplastic lymphoma kinase expression and bone marrow involvement pattern.
Park SH; Chi HS; Cho YU; Jang S; Park CJ
Histopathology; 2013 Jul; 63(1):13-8. PubMed ID: 23656317
[TBL] [Abstract][Full Text] [Related]
38. miR-497 suppresses cycle progression through an axis involving CDK6 in ALK-positive cells.
Hoareau-Aveilla C; Quelen C; Congras A; Caillet N; Labourdette D; Dozier C; Brousset P; Lamant L; Meggetto F
Haematologica; 2019 Feb; 104(2):347-359. PubMed ID: 30262555
[TBL] [Abstract][Full Text] [Related]
39. Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas.
Dejean E; Renalier MH; Foisseau M; Agirre X; Joseph N; de Paiva GR; Al Saati T; Soulier J; Desjobert C; Lamant L; Prósper F; Felsher DW; Cavaillé J; Prats H; Delsol G; Giuriato S; Meggetto F
Leukemia; 2011 Dec; 25(12):1882-90. PubMed ID: 21778999
[TBL] [Abstract][Full Text] [Related]
40. The c-Jun and JunB transcription factors facilitate the transit of classical Hodgkin lymphoma tumour cells through G
Zhang J; Wu Z; Savin A; Yang M; Hsu YR; Jantuan E; Bacani JTC; Ingham RJ
Sci Rep; 2018 Oct; 8(1):16019. PubMed ID: 30375407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]